OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Goetz on the Clinical Significance of Lasofoxifene in ER+/HER2- Breast Cancer

October 7th 2022

Matthew P. Goetz, MD, discusses the clinical significance of the phase 2 ELAINE-1 trial of lasofoxifene in patients with ESR1-mutated, estrogen receptor-positive/HER2-negative metastatic breast cancer.

Dr. Danilov on the Differences Between Covalent and Noncovalent BTK Inhibitors in MCL

October 7th 2022

Alexey V. Danilov, MD, PhD, discusses the key differences between covalent and noncovalent BTK inhibitors in mantle cell lymphoma.

Dr. Dasari on the Investigation of Fruquintinib in mCRC

October 6th 2022

Nageshwara Arvind Dasari, MD, discusses the patient population observed in the phase 3 FRESCO-2 trial in metastatic colorectal cancer.

Dr. Saba on Disparities of Clinical Trials in Head and Neck Cancer

October 6th 2022

Nabil Saba, MD, FACP, discusses the disparities seen in clinical trials in head and neck cancer.

Dr. Cristofanilli on Optimal Targeted Therapies in Metastatic HR-Positive Breast Cancer

October 5th 2022

Massimo Cristofanilli, MD, discusses the variety of targeted therapies available in metastatic hormone receptor–positive breast cancer.

Dr. Marshall on Genetic Testing in Gastrointestinal Cancer

October 5th 2022

John L. Marshall, MD, discusses the evolution of genetic testing in gastrointestinal cancer.

Dr. Cohen on the Treatment of Patients with Additional Comorbidities in CLL

October 5th 2022

Jonathon B. Cohen, MD, MS, discusses the evolution of treating patients with additional comorbidities in chronic lymphocytic leukemia.

Dr. Desai on Immune Checkpoint Inhibitors with Chemoradiation in Urothelial Cancer

October 5th 2022

Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.

Dr. Pakkala on Clinical Trial Enrollment for Patients With Breast Cancer and Brain Metastases

October 5th 2022

Suchita Pakkala, MD, discusses the importance for clinical trial enrollment for patients with breast cancer who have brain metastases.

Dr. Pinilla-Ibarz on Choosing Second-line BTK Inhibitors in CLL

October 5th 2022

Javier Pinilla-Ibarz, MD, PhD, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia.

Dr. Santa-Maria on Trastuzumab Deruxtecan in HER2-low TNBC

October 5th 2022

Cesar A. Santa-Maria, MD, discusses exploratory data seen with trastuzumab deruxtecan in patients with triple-negative breast cancer.

Dr. Johnson on the Evolution of Frontline Treatment in NSCLC

October 5th 2022

Melissa L. Johnson, MD, discusses the evolution of frontline treatment in non–small cell lung cancer.

Dr. Tkaczuk on the Utilization of Trastuzumab Deruxtecan in HER2+ Breast Cancer

October 5th 2022

Katherine Tkaczuk, MD, discusses the utilization of trastuzumab deruxtecan in HER2-positive breast cancer.

Dr. Strickler on the Importance of Targeted Therapies in HER2+ mCRC

October 5th 2022

John H. Strickler, MD, discusses the importance of investigating targeted therapies in HER2-positive metastatic colorectal cancer.

Dr. Ali on Ruxolitinib and Navitoclax Combination Therapy in Myelofibrosis

September 30th 2022

Haris Ali, MD, discusses the investigation of ruxolitinib and navitoclax combination therapy in myelofibrosis.

Dr. Wenham on the Importance of Clinical Trials in Ovarian Cancer

September 30th 2022

Robert Wenham, MD, MS, FACOG, FACS, discusses the importance of clinical trials in ovarian cancer.

Dr. Zhang on Multidisciplinary Approaches in Urothelial Cancer

September 30th 2022

Tian Zhang, MD, discusses the utilization of multidisciplinary approaches in urothelial cancers.

Dr. Kuykendall on Prognostication Factors in Myelofibrosis

September 29th 2022

Andrew Kuykendall, MD, discusses the evolution of prognostication factors in primary and secondary myelofibrosis.

Dr. Ornstein on Enfortumab Vedotin in Advanced Urothelial Carcinoma

September 29th 2022

Moshe Ornstein, MD, MA, discusses the use of the antibody-drug conjugate enfortumab vedotin in patients with advanced urothelial carcinoma that is refractory to chemotherapy and immunotherapy.

Dr. Arora on the Evolution of Treatment in Follicular Lymphoma

September 29th 2022

Madan L. Arora, MD, discusses the evolution of treatment in follicular lymphoma.